Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate

Clinical and Experimental Dermatology

Volumn 28, Issue 1, 2003, Pages 13-16

  Faghihi, G ^a,b   Tavakoli kia, R ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; PAROMOMYCIN; STIBOGLUCONATE SODIUM; UREA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCAR; SKIN LEISHMANIASIS; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INJECTIONS, INTRALESIONAL; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PAROMOMYCIN; TREATMENT OUTCOME;

EID: 0037275401     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2003.01169.x     Document Type: Article

References (13)

1. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
2. World Health Organization. Tropical Disease Research. 12th Program Report. UNDP/World Bank/WHO Special Program for Research and Training in Tropical Disease (TDR). Geneva: WHO, 1995: 135-49.
3. Dowlati Y. Cutaneous leishmaniasis: clinical aspects. Clin Dermatol 1996; 14: 425-31.
4. Zerehsaz F, Salmanpour R, Hanjani F et al. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. Int J Dermatol 1999; 38: 610-2.
5. Mujtaba G, Khalid M. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. Int J Dermatol 1999; 38: 607-9.
6. Ssamady JA, Schwartz RA. Old World cutaneous leishmaniasis. Int J Dermatol 1997; 36: 161-6.
7. Grevelink SA, Lerner EA. Leishmaniasis. J Am Acad Dermatol 1996; 34: 257-72.
8. Soto J, Hernandez N, Mejia H et al. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimoniate. Clin Infect Dis 1995; 20: 47-51.
9. Alkhawajah AM, Larbi E, Al-Gindan Y et al. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997; 91: 899-905.
10. Grogl M, Tina N, Thomason E, Franke D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous leishmaniasis. Am J Trop Med 1992; 47: 117-26.
11. Sharquie KE, Al-Talib K, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119: 53-7.
12. WHO Expert Committee. Control of Leishmaniasis. Technical Report Series 793. Geneva: WHO, 1990.
13. Sharquie KE. A new intralesional therapy for cutaneous leishmaniasis with hypertonic sodium chloride solution. J Dermatol (Japan) 1995; 22: 732-7.